Prognostic impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients
BACKGROUND: Emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) is associated with disease progression to advanced phases and reflects the genetic instability of CML. AIM: Is to evaluate the frequency of ACAs in chronic phase (CP) and advanced disease (AP) CML...
Gespeichert in:
Veröffentlicht in: | Open access Macedonian journal of medical sciences 2020-07, Vol.8 (B), p.623-630 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 630 |
---|---|
container_issue | B |
container_start_page | 623 |
container_title | Open access Macedonian journal of medical sciences |
container_volume | 8 |
creator | ElNahass, Yasser H. Assem, Magda M. Saber, Magdy M. Abdalla, Sarah K. Mahmoud, Hossam K. ElRefaey, Fatma A. |
description | BACKGROUND: Emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) is associated with disease progression to advanced phases and reflects the genetic instability of CML.
AIM: Is to evaluate the frequency of ACAs in chronic phase (CP) and advanced disease (AP) CML patients and study their impact on patient’s outcome, overall survival (OS) and event-free survival (EFS).
RESULTS: The studied group (n = 73) included 31 males (43%) and 42 females (57%). Median age of patients at diagnosis was 37 years (17–76). Median TLC was 208×109/L (2.1–784.2), median Hb was 9.4 g/dL (5.7–13), and median platelets count was 290.5×109/L (13–1271). We identified 32 patients (44%) with ACAs. ACAs emergence was significantly associated with advanced phases of CML (13/21, 62%) compared to CP (19/52, 36%) (p = 0.048). ACAs were associated with lower median OS and EFS in CP compared to AP (38 vs. 120 ms) and (58.3 vs. 77 ms) (p = 0.026 and p = 0.065, respectively). Early molecular responders (6/17, 35%) at 3 months, and 6 months (10/26, 38%) developed ACAs less than nonoptimal responders. Disease phase, hepatomegaly and bone marrow eosinophilia were significant predictors of OS (p < 0.001, p = 0.02, p = 0.04, respectively).
CONCLUSION: Early identification of ACAs in Ph+ metaphases at diagnosis and during therapy predicts CML outcome. ACAs emergence occurred at a higher frequency and at a younger age in our CML patients and are related to inferior EFS and OS. |
doi_str_mv | 10.3889/oamjms.2020.4259 |
format | Article |
fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_3889_oamjms_2020_4259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3889_oamjms_2020_4259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c111t-c4b9570aed6171a6578373f7708432b445f72a800ca103c6386dfd577c491bd33</originalsourceid><addsrcrecordid>eNpNkL1OwzAYRS0EElXpzugXSPlsx7EzVlX5kYLoAHPk2E5wie3KDkPfnpQyMN0j3as7HITuCayZlPVDVP7g85oChXVJeX2FFkRyUdQV59f_-Batcj4AAOF1RShdoGGf4hBinpzGzh-VnnDs8cYYN7kY1Ii3nyn6mKOfedOFmGaYO5uxC3g3nI6TU-F3FeaL15MdozO4sd9f1juF92rehinfoZtejdmu_nKJPh5379vnonl7etlumkITQqZCl13NBShrKiKIqriQTLBeCJAlo11Z8l5QJQG0IsB0xWRlesOF0GVNOsPYEsHlV6eYc7J9e0zOq3RqCbRnV-3FVXt21Z5dsR-iTl9T</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>ElNahass, Yasser H. ; Assem, Magda M. ; Saber, Magdy M. ; Abdalla, Sarah K. ; Mahmoud, Hossam K. ; ElRefaey, Fatma A.</creator><creatorcontrib>ElNahass, Yasser H. ; Assem, Magda M. ; Saber, Magdy M. ; Abdalla, Sarah K. ; Mahmoud, Hossam K. ; ElRefaey, Fatma A.</creatorcontrib><description>BACKGROUND: Emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) is associated with disease progression to advanced phases and reflects the genetic instability of CML.
AIM: Is to evaluate the frequency of ACAs in chronic phase (CP) and advanced disease (AP) CML patients and study their impact on patient’s outcome, overall survival (OS) and event-free survival (EFS).
RESULTS: The studied group (n = 73) included 31 males (43%) and 42 females (57%). Median age of patients at diagnosis was 37 years (17–76). Median TLC was 208×109/L (2.1–784.2), median Hb was 9.4 g/dL (5.7–13), and median platelets count was 290.5×109/L (13–1271). We identified 32 patients (44%) with ACAs. ACAs emergence was significantly associated with advanced phases of CML (13/21, 62%) compared to CP (19/52, 36%) (p = 0.048). ACAs were associated with lower median OS and EFS in CP compared to AP (38 vs. 120 ms) and (58.3 vs. 77 ms) (p = 0.026 and p = 0.065, respectively). Early molecular responders (6/17, 35%) at 3 months, and 6 months (10/26, 38%) developed ACAs less than nonoptimal responders. Disease phase, hepatomegaly and bone marrow eosinophilia were significant predictors of OS (p < 0.001, p = 0.02, p = 0.04, respectively).
CONCLUSION: Early identification of ACAs in Ph+ metaphases at diagnosis and during therapy predicts CML outcome. ACAs emergence occurred at a higher frequency and at a younger age in our CML patients and are related to inferior EFS and OS.</description><identifier>ISSN: 1857-9655</identifier><identifier>EISSN: 1857-9655</identifier><identifier>DOI: 10.3889/oamjms.2020.4259</identifier><language>eng</language><ispartof>Open access Macedonian journal of medical sciences, 2020-07, Vol.8 (B), p.623-630</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>ElNahass, Yasser H.</creatorcontrib><creatorcontrib>Assem, Magda M.</creatorcontrib><creatorcontrib>Saber, Magdy M.</creatorcontrib><creatorcontrib>Abdalla, Sarah K.</creatorcontrib><creatorcontrib>Mahmoud, Hossam K.</creatorcontrib><creatorcontrib>ElRefaey, Fatma A.</creatorcontrib><title>Prognostic impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients</title><title>Open access Macedonian journal of medical sciences</title><description>BACKGROUND: Emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) is associated with disease progression to advanced phases and reflects the genetic instability of CML.
AIM: Is to evaluate the frequency of ACAs in chronic phase (CP) and advanced disease (AP) CML patients and study their impact on patient’s outcome, overall survival (OS) and event-free survival (EFS).
RESULTS: The studied group (n = 73) included 31 males (43%) and 42 females (57%). Median age of patients at diagnosis was 37 years (17–76). Median TLC was 208×109/L (2.1–784.2), median Hb was 9.4 g/dL (5.7–13), and median platelets count was 290.5×109/L (13–1271). We identified 32 patients (44%) with ACAs. ACAs emergence was significantly associated with advanced phases of CML (13/21, 62%) compared to CP (19/52, 36%) (p = 0.048). ACAs were associated with lower median OS and EFS in CP compared to AP (38 vs. 120 ms) and (58.3 vs. 77 ms) (p = 0.026 and p = 0.065, respectively). Early molecular responders (6/17, 35%) at 3 months, and 6 months (10/26, 38%) developed ACAs less than nonoptimal responders. Disease phase, hepatomegaly and bone marrow eosinophilia were significant predictors of OS (p < 0.001, p = 0.02, p = 0.04, respectively).
CONCLUSION: Early identification of ACAs in Ph+ metaphases at diagnosis and during therapy predicts CML outcome. ACAs emergence occurred at a higher frequency and at a younger age in our CML patients and are related to inferior EFS and OS.</description><issn>1857-9655</issn><issn>1857-9655</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpNkL1OwzAYRS0EElXpzugXSPlsx7EzVlX5kYLoAHPk2E5wie3KDkPfnpQyMN0j3as7HITuCayZlPVDVP7g85oChXVJeX2FFkRyUdQV59f_-Batcj4AAOF1RShdoGGf4hBinpzGzh-VnnDs8cYYN7kY1Ii3nyn6mKOfedOFmGaYO5uxC3g3nI6TU-F3FeaL15MdozO4sd9f1juF92rehinfoZtejdmu_nKJPh5379vnonl7etlumkITQqZCl13NBShrKiKIqriQTLBeCJAlo11Z8l5QJQG0IsB0xWRlesOF0GVNOsPYEsHlV6eYc7J9e0zOq3RqCbRnV-3FVXt21Z5dsR-iTl9T</recordid><startdate>20200720</startdate><enddate>20200720</enddate><creator>ElNahass, Yasser H.</creator><creator>Assem, Magda M.</creator><creator>Saber, Magdy M.</creator><creator>Abdalla, Sarah K.</creator><creator>Mahmoud, Hossam K.</creator><creator>ElRefaey, Fatma A.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20200720</creationdate><title>Prognostic impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients</title><author>ElNahass, Yasser H. ; Assem, Magda M. ; Saber, Magdy M. ; Abdalla, Sarah K. ; Mahmoud, Hossam K. ; ElRefaey, Fatma A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c111t-c4b9570aed6171a6578373f7708432b445f72a800ca103c6386dfd577c491bd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>ElNahass, Yasser H.</creatorcontrib><creatorcontrib>Assem, Magda M.</creatorcontrib><creatorcontrib>Saber, Magdy M.</creatorcontrib><creatorcontrib>Abdalla, Sarah K.</creatorcontrib><creatorcontrib>Mahmoud, Hossam K.</creatorcontrib><creatorcontrib>ElRefaey, Fatma A.</creatorcontrib><collection>CrossRef</collection><jtitle>Open access Macedonian journal of medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ElNahass, Yasser H.</au><au>Assem, Magda M.</au><au>Saber, Magdy M.</au><au>Abdalla, Sarah K.</au><au>Mahmoud, Hossam K.</au><au>ElRefaey, Fatma A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients</atitle><jtitle>Open access Macedonian journal of medical sciences</jtitle><date>2020-07-20</date><risdate>2020</risdate><volume>8</volume><issue>B</issue><spage>623</spage><epage>630</epage><pages>623-630</pages><issn>1857-9655</issn><eissn>1857-9655</eissn><abstract>BACKGROUND: Emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) is associated with disease progression to advanced phases and reflects the genetic instability of CML.
AIM: Is to evaluate the frequency of ACAs in chronic phase (CP) and advanced disease (AP) CML patients and study their impact on patient’s outcome, overall survival (OS) and event-free survival (EFS).
RESULTS: The studied group (n = 73) included 31 males (43%) and 42 females (57%). Median age of patients at diagnosis was 37 years (17–76). Median TLC was 208×109/L (2.1–784.2), median Hb was 9.4 g/dL (5.7–13), and median platelets count was 290.5×109/L (13–1271). We identified 32 patients (44%) with ACAs. ACAs emergence was significantly associated with advanced phases of CML (13/21, 62%) compared to CP (19/52, 36%) (p = 0.048). ACAs were associated with lower median OS and EFS in CP compared to AP (38 vs. 120 ms) and (58.3 vs. 77 ms) (p = 0.026 and p = 0.065, respectively). Early molecular responders (6/17, 35%) at 3 months, and 6 months (10/26, 38%) developed ACAs less than nonoptimal responders. Disease phase, hepatomegaly and bone marrow eosinophilia were significant predictors of OS (p < 0.001, p = 0.02, p = 0.04, respectively).
CONCLUSION: Early identification of ACAs in Ph+ metaphases at diagnosis and during therapy predicts CML outcome. ACAs emergence occurred at a higher frequency and at a younger age in our CML patients and are related to inferior EFS and OS.</abstract><doi>10.3889/oamjms.2020.4259</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1857-9655 |
ispartof | Open access Macedonian journal of medical sciences, 2020-07, Vol.8 (B), p.623-630 |
issn | 1857-9655 1857-9655 |
language | eng |
recordid | cdi_crossref_primary_10_3889_oamjms_2020_4259 |
source | EZB-FREE-00999 freely available EZB journals |
title | Prognostic impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A01%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20of%20Additional%20Chromosomal%20Abnormalities%20in%20Egyptian%20Chronic%20Myeloid%20Leukemia%20Patients&rft.jtitle=Open%20access%20Macedonian%20journal%20of%20medical%20sciences&rft.au=ElNahass,%20Yasser%20H.&rft.date=2020-07-20&rft.volume=8&rft.issue=B&rft.spage=623&rft.epage=630&rft.pages=623-630&rft.issn=1857-9655&rft.eissn=1857-9655&rft_id=info:doi/10.3889/oamjms.2020.4259&rft_dat=%3Ccrossref%3E10_3889_oamjms_2020_4259%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |